Cross-Linked Hyaluronic Acid vs Non-Cross-Linked
Hyaluronic acid has become one of the most widely used ingredients in the aesthetics industry, appearing in everything from everyday skincare products to professional skin boosters and dermal fillers. However, not all hyaluronic acid products work in the same way.
One of the biggest differences comes down to whether the hyaluronic acid is cross-linked or non-cross-linked. Although both forms are designed to support hydration and improve the appearance of the skin, their structure, behaviour and suitability for different aesthetic treatments can vary considerably.
For UK aesthetics practitioners, understanding these differences is essential when selecting products, managing client expectations and recommending suitable treatments.
In this guide, we explain what cross-linked and non-cross-linked hyaluronic acid mean, how they work, their benefits and limitations, what the latest UK regulatory position means for practitioners, and what to consider when choosing between them.
Quick answer: Cross-linked hyaluronic acid has chemical bonds between its HA chains, forming a firmer gel that resists breakdown, so it is used in dermal fillers for volume and contour. Non-cross-linked hyaluronic acid has no added bonds, breaks down more readily and is mainly used for hydration in skincare and some skin boosters.
- Cross-linked HA is generally used in dermal fillers, with visible results typically lasting around 6 to 18 months.
- Non-cross-linked HA is generally used for hydration-focused products and is broken down more quickly.
- Neither is better in every case. Product formulation, intended use and manufacturer guidance matter more than cross-linking status alone.
What Is Hyaluronic Acid?
Hyaluronic acid (HA) is a naturally occurring substance found throughout the human body, particularly in the skin, joints and connective tissues.
It belongs to a group of molecules known as glycosaminoglycans and plays an important role in maintaining moisture, supporting tissue structure and helping the skin retain its elasticity.
One of hyaluronic acid’s most useful characteristics is its ability to bind water. This makes it particularly valuable in aesthetic treatments designed to improve skin hydration, smoothness and volume.
However, naturally occurring hyaluronic acid is continually broken down and replaced by the body. When used in aesthetic products, manufacturers can modify its molecular structure to influence how long it remains in the tissue and how it behaves after application or injection.
This is where cross-linking becomes important. For a wider look at how HA is valued clinically and commercially, read our article on valuing hyaluronic acid in aesthetics.
What Is Cross-Linked Hyaluronic Acid?
Cross-linked hyaluronic acid is hyaluronic acid that has been chemically modified to create connections between individual HA polymer chains.
These connections form a more stable, interconnected structure that generally makes the material more resistant to enzymatic breakdown.
In aesthetic medicine, cross-linking is particularly important in the manufacture of hyaluronic acid dermal fillers.
Without modification, injected hyaluronic acid would generally break down relatively quickly. Cross-linking helps create a longer-lasting material that can provide structural support, volume and contouring.
How Does Cross-Linking Work?
During manufacturing, hyaluronic acid chains are connected using a chemical cross-linking agent.
One commonly used agent in HA dermal fillers is BDDE (1,4-butanediol diglycidyl ether).
The cross-linking process creates a three-dimensional network, producing a gel with properties that differ from unmodified hyaluronic acid.
Depending on the formulation, this can influence:
- Viscosity: How easily the gel flows.
- Elasticity: How the gel responds to deformation and maintains its structure.
- Cohesivity: How well the gel holds together.
- Resistance to degradation: How quickly the material is broken down within the body.
- Water uptake: How the gel interacts with surrounding moisture.
Importantly, the degree of cross-linking is not the only factor determining how a filler behaves. HA concentration, molecular weight, manufacturing technology and gel structure all influence the finished product.
This explains why two dermal fillers containing cross-linked hyaluronic acid can have very different characteristics.
What Is Cross-Linked Hyaluronic Acid Used For?
Cross-linked HA is commonly associated with injectable dermal fillers used to enhance facial volume and contour.
Depending on the product’s approved intended purpose, treatment areas and practitioner competence, applications may include:
- Lip enhancement and definition.
- Cheek volume enhancement.
- Softening the appearance of nasolabial folds.
- Chin and jawline contouring.
- Helping improve the appearance of selected facial lines and wrinkles.
- Supporting the appearance of facial volume associated with ageing.
Different formulations are developed for different purposes. A softer, more flexible filler may be appropriate for one anatomical area, while a firmer gel with greater structural support may be needed elsewhere. Our guide to dermal fillers for aesthetic practitioners looks at treatment areas and product matching in more detail.
Practitioners should always follow the manufacturer’s instructions for use rather than assuming that all cross-linked fillers are interchangeable.
What Is Non-Cross-Linked Hyaluronic Acid?
Non-cross-linked hyaluronic acid is HA that has not undergone the chemical cross-linking process used to create a stabilised gel network.
Its molecular chains remain unconnected by these additional chemical bonds, meaning the material generally has different flow characteristics and is more readily broken down by the body.
Non-cross-linked HA is commonly found in topical skincare products and certain professional skin hydration formulations.
Unlike conventional volumising dermal fillers, non-cross-linked HA products are generally selected for their hydrating properties rather than their ability to provide sustained structural volume.
How Does Non-Cross-Linked Hyaluronic Acid Work?
Non-cross-linked hyaluronic acid attracts and binds water, helping support moisture retention.
In topical skincare, its effects depend partly on molecular size and formulation. Larger HA molecules primarily help hydrate the skin’s surface, while smaller molecular-weight forms may interact differently with the outer layers of the skin.
When used in an appropriately authorised injectable formulation, non-cross-linked HA can contribute to tissue hydration. However, its effects and duration depend on the specific product, treatment technique and client characteristics.
Because it does not have the same stabilised network as cross-linked filler gels, non-cross-linked HA is generally unsuitable for treatments requiring sustained projection or structural support.
What Is Non-Cross-Linked Hyaluronic Acid Used For?
Depending on the formulation and its intended purpose, non-cross-linked HA may be found in:
- Hydrating facial serums and moisturisers.
- Professional skincare treatments.
- Some injectable skin hydration products.
- Selected mesotherapy formulations.
- Products designed to improve the appearance of dehydrated skin.
It’s important to distinguish between topical hyaluronic acid and products intended for injection. A cosmetic serum must never be injected simply because it contains hyaluronic acid.
Similarly, not every product marketed as a skin booster is non-cross-linked. Some contain stabilised or lightly cross-linked HA, while others combine HA with additional ingredients.
Where Do Stabilised and Hybrid HA Products Fit?
The cross-linked versus non-cross-linked split is a useful starting point, but it is not a strict binary. Some injectable products sit between the two categories:
- Lightly cross-linked or stabilised HA: Modified enough to last longer than plain HA, but formulated for hydration rather than volume.
- Hybrid HA complexes: For example, the manufacturer of Profhilo describes its product as a hybrid of high and low molecular weight HA made using a heat-based process rather than chemical cross-linking agents.
- HA combined with other ingredients: Such as HA with amino acids, as in the Jalupro range.
Always check the manufacturer’s composition and instructions for use rather than relying on the marketing category.
Cross-Linked vs Non-Cross-Linked Hyaluronic Acid: Key Differences
Although both forms share the same underlying ingredient, their practical applications can be quite different.
| Feature | Cross-Linked Hyaluronic Acid | Non-Cross-Linked Hyaluronic Acid |
|---|---|---|
| Structure | HA chains connected through chemical cross-links | HA chains without additional chemical cross-links |
| Primary purpose | Often used for volume, contour and structural support | Often used for hydration and skin conditioning |
| Texture | Typically forms a more structured gel | Generally more fluid, depending on concentration and formulation |
| Breakdown | Generally more resistant to degradation | Generally breaks down more readily |
| Longevity | Many dermal fillers provide effects lasting several months or longer | Effects are generally shorter-lived, particularly when injected without stabilisation |
| Common products | Volumising dermal fillers and some stabilised skin boosters | Hydrating skincare and certain skin booster formulations |
| Volume enhancement | Can provide sustained volume depending on the formulation | Generally provides limited sustained structural volume |
These are general characteristics rather than fixed rules. Individual products can behave differently depending on their manufacturing process, HA concentration and other formulation factors.
Which Type of Hyaluronic Acid Lasts Longer?
One of the most frequently asked questions about cross-linked and non-cross-linked hyaluronic acid is how long each lasts.
Generally speaking, cross-linked hyaluronic acid lasts longer within the tissues because its stabilised structure makes it more resistant to degradation.
The NHS notes that dermal fillers usually last between 6 and 18 months, although some formulations may last for shorter or longer periods. Our guide to how long dermal fillers actually last covers this in more depth.
The duration of results depends on several factors, including:
- The specific filler formulation and degree of stabilisation.
- The anatomical area being treated.
- The amount of product administered.
- Individual client metabolism and tissue characteristics.
- Facial movement and mechanical stresses.
- The treatment technique and product placement.
Non-cross-linked HA generally breaks down more quickly when injected. However, the duration of visible skin improvements should not be confused with the time the HA itself remains in the tissue.
For example, a skin hydration treatment may produce effects that continue beyond the period during which the original HA molecules remain present.
Equally, cross-linked fillers can sometimes remain detectable in tissues beyond their advertised duration of visible results.
Practitioners should avoid guaranteeing specific treatment longevity and instead explain the expected outcomes for the individual product and client.
Cross-Linked Hyaluronic Acid in Dermal Fillers
Cross-linked hyaluronic acid is particularly important in modern dermal filler treatments because it allows manufacturers to produce gels with different mechanical properties.
These properties are often described using the term rheology, which refers to how a material flows and deforms when force is applied.
Why Filler Rheology Matters
Not all dermal fillers need to behave in the same way.
For example, a product intended for structural support may require different characteristics from one intended for superficial correction or use in a highly mobile area.
Two important properties include:
- G’ (elastic modulus): A measure of how strongly a gel resists deformation under specific testing conditions.
- Cohesivity: The tendency of a gel to remain together rather than separate.
However, a higher G’ does not automatically mean a filler is better or more suitable for every treatment.
The correct product depends on its intended use, the client’s anatomy, the treatment objective and the manufacturer’s guidance.
Examples of Hyaluronic Acid Dermal Fillers
At Aesthetics Wise, we supply professional aesthetic products to registered practitioners, including HA dermal filler ranges such as Revolax, Purilax and Regenovue. Other HA filler ranges include Neuramis, Nexfill, Kairax, Lumifil and Restylane.
Different products within these ranges are formulated for different treatment objectives, with variations in gel characteristics and intended applications.
When comparing dermal fillers, practitioners should consider more than simply the brand or price. Product specifications, regulatory status, traceability, training requirements and suitability for the intended procedure are all important.
Non-Cross-Linked Hyaluronic Acid in Skin Boosters
Skin boosters have become an increasingly popular treatment category in the UK aesthetics industry, particularly among clients looking to improve skin hydration and overall appearance without necessarily changing their facial contours.
Non-cross-linked hyaluronic acid is used in some skin booster formulations because of its water-binding properties.
However, the skin booster category is broader than non-cross-linked HA alone.
Some products contain stabilised hyaluronic acid, others use combinations of high and low molecular weight HA, and some include additional ingredients intended to support particular skin-related outcomes. Our skin boosters category includes HA-based ranges such as Jalupro and Seventy Hyal, as well as polynucleotide-based ranges such as Plinest and Nucleofil.
What Can Hyaluronic Acid Skin Boosters Help With?
Depending on the specific product and supporting clinical evidence, HA-based skin boosters may be used to address concerns such as:
- Skin dehydration.
- The appearance of fine lines associated with dryness.
- Reduced skin smoothness.
- Dull-looking skin.
- Changes in skin texture.
Claims about improvements in elasticity, collagen production or skin remodelling should be supported by evidence for the particular formulation rather than assumed from the presence of hyaluronic acid alone.
Practitioners should also distinguish HA-based skin boosters from other injectable categories, such as polynucleotide treatments, which use different active substances and have different proposed mechanisms of action. Our comparison of skin boosters vs polynucleotides explains the difference.
Can Cross-Linked and Non-Cross-Linked Hyaluronic Acid Be Used Together?
Yes, different HA-based treatments may form part of a wider aesthetic treatment plan, provided each product is suitable for the client and the proposed combination is clinically appropriate.
For example, a client might be concerned about both facial volume loss and skin dehydration.
In this situation, a qualified practitioner may assess whether a volumising dermal filler and a separate skin hydration treatment could address those concerns.
However, the treatments serve different purposes.
A cross-linked filler may be selected to provide volume or contour, while a skin booster may be considered for hydration-related concerns.
These products should not be mixed, layered or administered together unless the manufacturers’ instructions, relevant evidence and clinical assessment support doing so.
Treatment sequencing, anatomical considerations, potential interactions and complication management should all be considered before proceeding.
What Are the Risks of Hyaluronic Acid Fillers and Skin Boosters?
Hyaluronic acid fillers are widely used in aesthetic medicine, but neither cross-linked nor non-cross-linked injectable HA is risk-free.
Common temporary reactions following injectable treatments can include swelling, redness, tenderness and bruising.
More significant complications may include infection, inflammatory nodules, delayed reactions, filler moving away from the intended area and vascular occlusion. The NHS lists infection, lumps, scarring and blocked blood vessels among the rarer serious problems.
Vascular occlusion is a particularly serious complication of dermal filler treatment. Accidental injection into a blood vessel, or compression affecting blood flow, can lead to tissue damage and, in rare cases, visual impairment or blindness.
These risks make appropriate anatomical knowledge, client assessment, training and emergency preparedness essential.
Can Hyaluronic Acid Fillers Be Dissolved?
Hyaluronic acid fillers can often be broken down using an enzyme called hyaluronidase.
Hyaluronidase may be used by appropriately qualified healthcare professionals in the management of certain HA filler complications or unwanted results.
However, not all HA fillers dissolve at the same rate or respond identically, and treatment outcomes cannot be guaranteed.
In the UK, injectable hyaluronidase is a prescription-only medicine. Since 1 June 2025, nurse and midwife prescribers must hold a face-to-face consultation before prescribing it, and other prescribers are expected to do the same. It cannot simply be bought and held as clinic stock, so practitioners should arrange access through a prescriber and a pharmacy in line with medicines law and JCCP guidance on face-to-face prescribing.
Practitioners should have an appropriate complication management pathway, including timely access to suitably qualified medical support.
UK Regulations for Hyaluronic Acid Fillers and Skin Boosters in 2026
For UK aesthetics businesses, product selection is about more than understanding the science. Practitioners and employers must also consider product regulation, professional responsibilities, client safety and appropriate treatment governance.
UK regulation is changing quickly. The position below is current as at 10 November 2026, but you should check official sources before relying on it.
Medical Device Regulations
Injectable HA dermal fillers are regulated as medical devices rather than prescription-only medicines, so they are not supplied against a prescription. How other injectables, including some skin boosters, are classified depends on the product and its intended purpose, so check the manufacturer’s documentation.
In Great Britain, medical devices are regulated under the UK Medical Devices Regulations 2002, as amended, with oversight from the Medicines and Healthcare products Regulatory Agency (MHRA). Manufacturers can use UKCA marking, and CE-marked devices are currently accepted under transitional arrangements.
On 21 October 2026 the government confirmed that it will continue to accept CE-marked medical devices on a long-term basis. Legislation is still needed to put this into effect, so the existing transitional dates (30 June 2028 or 30 June 2030, depending on the device type) remain the legal position until then.
Continued recognition of CE marking does not remove other duties. Manufacturers of CE-marked devices placed on the Great Britain market must still appoint a UK responsible person, register with the MHRA and meet post-market surveillance requirements. Practitioners and suppliers should check these details rather than assuming that CE marking, UKCA marking or overseas approval automatically establishes compliance in every circumstance.
Arrangements in Northern Ireland differ, because CE marking is required for devices placed on the Northern Ireland market.
Official guidance is available from the MHRA and through GOV.UK’s guidance on regulating medical devices in the UK.
Who Can Administer Injectable Hyaluronic Acid?
There is no single UK-wide licensing framework that applies identically to every non-surgical cosmetic procedure or every practitioner. Requirements vary according to the procedure, professional status and the nation in which the treatment takes place.
England. The Health and Care Act 2022 gave ministers the power to introduce a licensing scheme for non-surgical cosmetic procedures, but no licensing scheme is in force at the time of writing. In August 2025 the government confirmed a risk-based approach, with local authority licensing for lower-risk procedures and Care Quality Commission (CQC) regulation for the highest-risk ones.
On 21 October 2026 the Department of Health and Social Care opened a consultation on restricting high-risk cosmetic and wellbeing procedures in England, which closes on 13 January 2027. Under the proposals, listed procedures would be limited to doctors, dentists and independent prescribing nurses, midwives and pharmacists working through CQC-registered providers. The procedures listed include cosmetic surgery (including filler procedures outside the face), non-resorbable facial fillers, deep chemical peels, dermal microcoring, subcision, intravenous procedures and PRP.
As published, the consultation document does not name resorbable facial fillers such as HA among the high-risk procedures. These are proposals only, and the licensing of lower-risk procedures is to follow later with no timeline given, so practitioners should monitor developments rather than assume the current position will last.
Scotland. The Non-surgical Procedures and Functions of Medical Reviewers (Scotland) Act 2026 was passed in March 2026 and received Royal Assent on 12 May 2026. It covers injectable procedures and creates offences for providing specified procedures to under-18s or outside permitted premises. The main offences are brought into force by commencement regulations, so check their current status before relying on them.
Wales and Northern Ireland. Each has its own regulatory arrangements, which must be checked separately with the relevant regulator.
Professional registration, where applicable, does not automatically establish competence to perform every injectable aesthetic treatment. Businesses should ensure that practitioners have suitable training, insurance, anatomical knowledge and access to appropriate clinical oversight.
Client Consultation and Informed Consent
Before carrying out an injectable HA treatment, practitioners should undertake and document an appropriate consultation.
This should include:
- A review of the client’s medical history and relevant medications.
- Assessment of the treatment area and individual anatomy.
- Discussion of the proposed product and expected outcomes.
- Explanation of potential side effects and serious complications.
- Consideration of contraindications and alternative treatments.
- Confirmation that the client understands the treatment limitations.
- Documented informed consent.
- Clear aftercare advice and emergency contact arrangements. See our guides to dermal filler aftercare in the first 48 hours and exercising after dermal fillers or skin boosters.
Practitioners should also be aware that administering cosmetic fillers to people under 18 is prohibited in England under the Botulinum Toxin and Cosmetic Fillers (Children) Act 2021, subject to limited medical exceptions. The government has also said it intends to introduce wider age restrictions as part of its reforms. Scotland has legislated for its own under-18 restriction, and other UK nations have their own applicable requirements, which must be checked separately.
Product Traceability and Record Keeping
Good record keeping is particularly important for injectable aesthetic products.
Practitioners should record the product name, manufacturer, batch or lot number, expiry date, treatment details and relevant client information.
Maintaining these records helps businesses respond to product recalls, investigate adverse reactions and demonstrate appropriate professional standards.
Suspected problems involving medical devices can be reported through the MHRA’s Yellow Card scheme.
Client records must also be handled in accordance with applicable data protection requirements, including UK GDPR.
How to Choose the Right Hyaluronic Acid Product for Your Aesthetics Clinic
With so many dermal fillers and skin boosters available, choosing the right product requires more than comparing HA concentrations or treatment prices.
Here are six practical considerations for UK aesthetics professionals.
1. Start With the Treatment Objective
Consider what the client actually wants to achieve.
Are they looking to enhance volume, improve facial contours or address dehydration and skin texture?
These objectives may require very different products, and in some cases an injectable treatment may not be appropriate at all.
2. Check the Product’s Intended Use
Always review the manufacturer’s instructions for use, including approved or stated treatment areas, contraindications and administration requirements.
Do not assume that a product can be used for a particular procedure simply because another HA product is commonly used for that purpose.
3. Understand the Formulation
For dermal fillers, consider factors such as rheological properties, HA concentration and the manufacturer’s clinical evidence.
For skin boosters, examine the type of HA used, whether it is stabilised, any additional ingredients and the evidence supporting the claimed benefits.
4. Buy From a Reputable UK Supplier
Purchasing from a reliable supplier helps support product authenticity, appropriate storage, batch traceability and access to relevant product information. Ask whether the manufacturer is registered with the MHRA, whether a UK responsible person is named, and whether the supplier verifies that buyers are registered practitioners.
At Aesthetics Wise, we understand the importance of dependable product sourcing for professional aesthetics businesses. Learn more about Aesthetics Wise or see how we work as a UK aesthetics wholesaler.
Whether you’re stocking up on dermal fillers, skin boosters or other clinic essentials, it’s important to choose products that meet your professional requirements and are suitable for their intended use.
5. Consider Storage and Stock Management
Different injectable products may have different storage requirements.
Always follow the manufacturer’s stated temperature limits, shelf-life guidance and handling instructions.
For clinics carrying multiple filler and skin booster ranges, a first-expiry, first-out stock rotation system can help minimise wastage.
Maintaining accurate stock records also makes it easier to track batches and identify products approaching their expiry dates.
6. Review Treatment Costs and Profitability
Product price is an important commercial consideration, but it shouldn’t be the deciding factor in treatment selection.
When calculating treatment profitability, aesthetics business owners should consider the full cost of delivering a responsible and professional service. Our article on whether bulk buying increases profit looks at one part of this.
This may include:
- The purchase cost of the product.
- VAT treatment and applicable supplier charges.
- Consumables and personal protective equipment.
- Practitioner time and clinical overheads.
- Insurance and training costs.
- Waste disposal and stock losses.
- Aftercare and complication management provisions.
For example, a product with a lower purchase price may not necessarily deliver better overall value if it is unsuitable for the treatment, has a shorter remaining shelf life or requires additional operational costs.
Equally, a more expensive product is not automatically clinically superior.
Client safety, product suitability and regulatory compliance must always come before commercial considerations.
Common Misconceptions About Cross-Linked and Non-Cross-Linked Hyaluronic Acid
Myth 1: Cross-Linked Hyaluronic Acid Is Always Better
Not necessarily. Cross-linked HA is particularly useful where sustained structure and volume are required, but that does not make it the best option for every treatment.
Non-cross-linked HA can be highly suitable for certain hydration-focused formulations.
The best choice depends on the intended purpose and the individual product.
Myth 2: All Skin Boosters Contain Non-Cross-Linked HA
This is incorrect. Some skin boosters use non-cross-linked HA, while others contain stabilised or lightly cross-linked formulations, hybrid complexes or entirely different active ingredients.
Practitioners should examine the product specifications rather than relying on the marketing category alone. For more, see our guide to debunking skin booster myths.
Myth 3: More Cross-Linking Means a Better Dermal Filler
A higher degree of cross-linking can influence a gel’s stability and mechanical properties, but it does not automatically improve clinical outcomes.
Different treatments require different characteristics, and excessive stiffness or unsuitable product placement can create undesirable results.
Myth 4: Hyaluronic Acid Treatments Are Completely Risk-Free
Although HA is naturally present in the body, injectable treatments still carry risks.
Product formulation, injection technique, anatomy, client factors and practitioner competence all influence outcomes.
Understanding the Difference Matters
Cross-linked and non-cross-linked hyaluronic acid both have important roles within modern aesthetics, but understanding their differences is essential when selecting professional treatments and products.
Cross-linked hyaluronic acid is generally more resistant to breakdown and is commonly used in dermal fillers designed to provide volume, contour and structural support.
Non-cross-linked hyaluronic acid is generally more readily degraded and is widely used in skincare and certain hydration-focused skin booster formulations.
Neither is inherently better. The right choice depends on the treatment objective, product formulation, clinical evidence and individual client needs.
For UK aesthetics practitioners, combining a sound understanding of HA technology with responsible product sourcing, appropriate training and strong client safety procedures is the best approach to delivering consistent, professional treatments.
At Aesthetics Wise, we supply a range of professional aesthetics products, including dermal fillers and skin boosters, helping UK clinics and registered practitioners access the products they need for their businesses.
Registered practitioners can explore our range at aestheticswise.com, read our FAQs or contact the team with any questions.
Further Reading and Professional Resources
- GOV.UK: Restrictions on the performance of high-risk cosmetic and wellbeing procedures in England: Consultation opened 21 October 2026 and closing 13 January 2027.
- MHRA: Government confirms indefinite recognition of CE marked medical devices: Announcement published 21 October 2026.
- MHRA: Regulating Medical Devices in the UK: Official information on medical device requirements, conformity assessment and placing products on the UK market.
- Medicines and Healthcare products Regulatory Agency: UK regulator responsible for medicines and medical device safety.
- Botulinum Toxin and Cosmetic Fillers (Children) Act 2021: Legislation restricting cosmetic injectable procedures for under-18s in England.
- Non-surgical Procedures and Functions of Medical Reviewers (Scotland) Act 2026: Scottish legislation on non-surgical procedures.
- JCCP: Face-to-face prescribing requirement: Guidance on prescribing for cosmetic injectables since 1 June 2025.
- MHRA Yellow Card Scheme: Reporting suspected adverse incidents involving medicines and medical devices.
- NHS: Face and lip fillers (dermal fillers): Independent information about dermal filler procedures, risks and client considerations.
- Journal of Clinical and Aesthetic Dermatology: Clinical research and professional articles covering injectable aesthetic treatments and dermatology.
- Aesthetics Wise Hot Topics: More practitioner guides on products, aftercare and running a clinic.
Professional information: This article is intended for general educational purposes and does not replace product-specific instructions, clinical training, professional advice or applicable regulatory requirements. Regulatory status and treatment suitability should always be verified for the individual product and UK jurisdiction.


















